摘要
目的:评价EGFR-TKI联合同步放疗治疗EGFR突变型转移性非小细胞肺癌的疗效及安全性。方法:对2011年3月至2014年3月我院收治的EGFR突变型转移性非小细胞肺癌患者60例的临床资料进行统计分析。结果:联合治疗组患者治疗的总有效率83.3%(25/30)高于单独治疗组53.3%(16/30),差异具有统计学意义(P<0.05),PFS、OS均长于单独治疗组,差异具有统计学意义(P<0.05),1年、2年生存率66.7%(20/30)、13.3%(4/30)均高于单独治疗组43.3%(13/30)、3.3%(1/30),差异具有统计学意义(P<0.05),但两组患者的皮疹、腹泻、恶心、呕吐、乏力、贫血、白细胞减少、血小板减少、放射性肺炎、放射性食管炎、放射性脑病等不良反应发生率之间的差异不具有统计学意义(P>0.05)。结论:EGFR-TKI联合同步放疗治疗EGFR突变型转移性非小细胞肺癌安全有效。
Objective： To evaluate the efficacy and safety of EGFR -TKI with concurrent radiotherapy in the treatment of EGFR mutant metastatic non -small cell lung cancer.Methods：The clinical data of 60 cases of patients with EGFR mutant metastatic non -small cell lung cancer in our hospital from March 2011 to March 2014 were statistically analyzed.Results：The total effective rate of the combination therapy group 83.3%（25 /30） was significantly higher than the monotherapy group 53.3% （16/30） （P 〈0.05）, the PFS, OS were sig-nificantly longer （P 〈0.05）, the 1 year, 2-year survival rate 66.7% （20/30）, 13.3% （4/30） were signifi-cantly higher than the monotherapy group 43.3% （13/30）, 3.3% （1/30） （P 〈0.05）, but the differences of the rates of adverse events of rash, diarrhea, nausea, vomiting, fatigue, anemia, leukopenia, thrombocytope-nia, radiation pneumonitis, esophagitis, radiation encephalopathy between the two groups were not significant （P〉0.05）.Conclusion：EGFR-TKI with concurrent radiotherapy in the treatment of EGFR mutant metastatic non-small cell lung cancer is safe and effective .
出处
《河北医学》
CAS
2016年第8期1268-1271,共4页
Hebei Medicine
基金
江苏大学医学临床科技发展基金
(编号:JLY20140159)
